17 April 2012
4 - 5pm
Venue: Ground Floor Seminar Room (G010), UniServices House, 70 Symonds Street, Auckland
A Bioengineering research seminar by Dr Donald Wlodkowic, Director The BioMEMS Research Group, The University of Auckland
Medicine and biological sciences are, more than ever, becoming highly dependent on technological and multidisciplinary approaches that warrant advanced analytical and therapeutic accomplishments.
In this regard, microfluidic Lab‐on‐a‐Chip (LOC) technologies are perhaps the most groundbreaking offshoots of biomedical engineering enabling design of an entirely new generation of bioinstrumentation. LOC are the next generation of analytical laboratories that have been miniaturised to the size of a matchbox but at the same time can automatically perform many parallel and complex biomedical experiments faster, cheaper and much more efficiently.
Biomicrofluidic technologies, represent a unique approach to combine micro-scale engineering and material sciences, with specific biomedical questions, providing technological advances that allow for fundamentally new capabilities in the spatiotemporal analysis of molecules, cells, tissues and small model organisms. These technologies experience an explosive growth worldwide with a substantial promise of a direct impact on disease diagnosis and treatment.
This talk will outline several examples from our portfolio of Lab-on-a-Chip technologies for biomedicine and biotechnology. My talk will have a special emphasis on integrated LOC technologies for automated manipulation of small model organism and real-time bioanalysis in drug discovery and toxicology.
About Dr Donald Wlodkowic
Dr Donald Wlodkowic is a director of the BioMEMS Research Group at The University of Auckland. Since 2011 he has been appointed as an Adjunct Associate Professor at the School of Applied Sciences, RMIT University. His work concentrates on development of disruptive microfluidic (Lab-on-a-Chip) technologies, micro-electromechanical systems (MEMS) as well as biomedical laboratory automation that can transform medical diagnostics, drug discovery, environmental monitoring and support development of a new generation of early-warning systems for biodefence.